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Abstract 
Mutations in genes encoding aaRSs (aminoacyl-tRNA synthetases) have been 
reported in several neurological disorders. KARS is a dual localized lysyl-tRNA 
synthetase (LysRS) and its cytosolic isoform belongs to the multiple aminoacyl-tRNA 
synthetase complex (MSC). Biallelic mutations in KARS gene were described in a 
wide phenotypic spectrum ranging from non-syndromic deafness to complex 
impairments. Here, we report on a patient with severe neurological and neurosensory 
disease investigated by whole exome sequencing and found to carry biallelic 
mutations c.683C>T (p.Pro228Leu) and c.871T>G (p.Phe291Val), the second one 
being novel, in the KARS gene. The patient presented with an atypical clinical 
presentation with an optic neuropathy not previously reported. At the cellular level, 
we show that cytoplasmic KARS was expressed at a lower level in patient cells and 
displayed decreased interaction with MSC. In vitro, these two KARS variants have a 
decreased aminoacylation activity compared to wild type KARS, the p.Pro228Leu 
being the most affected. Our data suggest that dysfunction of cytoplasmic KARS 
resulted in decreased level of translation of the nuclear encoded lysine rich proteins 
belonging to the respiratory chain complex, thus impairing mitochondria functions.  
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Graphical Abstract 
Here, we report on a patient with severe neurological disease, found to carry 
biallelic mutations c.683C>T (p.Pro228Leu) and c.871T>G (p.Phe291Val) in the 
lysyl-tRNA synthetase KARS. 
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lysyl-tRNA synthetase, translation, aaRS, neurological disorder, optic neuropathy, 
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Introduction 
Aminoacyl-tRNA synthetases (aaRS) belong to a ubiquitously expressed group of 
enzymes responsible for aminoacylation, the process of attaching amino acids to their 
cognate tRNA. In humans, 37 aaRS proteins are encoded by nuclear genes. These 
enzymes can be divided into 3 groups according to the cellular compartment where 
the aminoacylation is performed: cytoplasm, mitochondria or both. KARS is one of 
the 3 human aaRS with a dual localization and its cytosolic isoform is a component of 
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a multiple aminoacyl-tRNA synthetase complex (MSC) (Havrylenko & Mirande, 
2015). This complex increases the efficiency of protein synthesis and is composed of 
at least nine aaRS and three accessory proteins (p18, p38 and p43). The p38/AIMP2 
scaffold protein serves as a cytoplasmic anchor to retain KARS in the complex 
(Kaminska et al., 2009; Quevillon et al., 1999). The phosphorylation at the serine in 
position 207 (P-S207) of the KARS protein induces its release from the MSC and its 
translocation into the nucleus for non-canonical activities in transcription (Debard et 
al., 2017; Ofir-Birin et al., 2013). The P-S207 KARS leads also to increased levels of 
diadenosine tetraphosphate (Ap4A), a second messenger acting as a positive regulator 
of the microphthalmia-associated transcription factor (MITF) (Lee, Nechushtan, 
Figov, & Razin, 2004). Interestingly, increased levels of Ap4A were observed in tears 
of patients with dry eye and with congenital aniridia (Peral et al., 2006; Peral et al., 
2015), and in the aqueous humour from patients with primary open-angle glaucoma 
(Castany et al., 2011). 
Mutations in genes encoding aaRS are reported in a wide spectrum of inherited human 
disorders (Antonellis & Green, 2008; Sauter et al., 2015). Mutations in genes 
encoding mitochondrial aaRS are associated with autosomal recessive isolated or 
syndromic phenotypes involving tissues with high metabolic needs such as brain, 
muscle, heart, and liver (Gotz et al., 2011; Sofou et al., 2015). Mutations in genes 
encoding cytoplasmic aaRS are implicated in different disorders, including 
neurological diseases, with autosomal recessive or dominant inheritance (Latour et al., 
2010). Mutations in the KARS gene (MIM# 601421), encoding the lysyl-tRNA 
synthetase, were described initially in peripheral neuropathy (McLaughlin et al., 2010) 
and few years later in non syndromic hearing loss (Santos-Cortez et al., 2013). A wide 
range of clinical features was reported in patients carrying biallelic mutations in KARS 
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including phenotypes suggesting mitochondrial disorder (Kohda et al., 2016; Lieber et 
al., 2013; McMillan et al., 2015; Murray et al., 2017; Verrigni et al., 2017; Zhou et al., 
2017). 
Here, we report a patient, with biallelic variants in KARS identified by whole exome 
sequencing, who presented with severe neurological and neurosensory impairment. 
Interestingly, while in the patient’s fibroblasts the expression of the mitochondrial 
isoform of the protein was slightly increased, a reduced activity of the complexes I 
and IV was observed in the patient’s skeletal muscle which is compatible with a 
mitochondrial disorder. Although this first result seemed contradictory, we questioned 
whether the dysfunction of the patient’s respiratory chain could be related to a 
decreased expression of some members of complex I and IV encoded by the nuclear 
genome, thus translated into the cytoplasm and afterwards imported into the 
mitochondria. Indeed, a lower amount of the cytoplasmic isoform of KARS was 
observed in the patient’s cells. At the molecular level, using a yeast two-hybrid 
interaction assay, we observed a decreased interaction between KARS bearing either 
of the patient mutations and p38, the interaction partner of KARS in the MSC 
complex. The association of KARS into the MSC complex controls its canonical 
function in translation from those non-canonical as the regulation of transcription. 
This study suggests that a dysfunction in cytoplasmic KARS due to the patient’s 
missense mutations decreased the efficiency of translation of the nuclear encoded 
lysine rich proteins belonging to respiratory chain complexes, thus impairing 
mitochondria functions. 
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Materials and Methods 
Standard protocol approvals and patient consents 
After informed consent of the patient and her parents according to the French 
legislation, peripheral blood samples were obtained from the affected individual and 
her parents as well as control individuals. DNA from all collected samples was 
extracted according to standard procedures. The objectives and the aim of the study 
were clearly explained to the patient and this study was approved by the local ethics 
committee at Hôpitaux Universitaires de Strasbourg (Strasbourg University Hospital). 
Mutational analysis 
Whole exome sequencing was performed in the affected individual (II-1) and the 
healthy parents (I-1 and I-2). Exons of DNA samples were captured with in-solution 
enrichment methodology (Agilent SureSelect XT Clinical Research Exome – 54 Mb) 
and paired-end 75 bases massively parallel sequencing was performed on Illumina 
HiSeq. 4000 instrument. SNP and INDEL variant calling were performed with 
CASAVA1.8.2.  
Exome data processing, variant calling and variant annotation were performed using 
VaRank (Geoffroy et al., 2015). We excluded variants present in dbSNP144 and 
annotated as non-pathogenic (using the “ClinicalSignificance” field) validated by at 
least 2 methods (using the “Validation Status” field) and variants with an allele 
frequency of more than 1% in the dbSNP database (Sherry et al., 2001), the Exome 
Variant Server (http://evs.gs.washington.edu/EVS/), the 1000Genomes (Genomes 
Project et al., 2015), the ExAC Browser database (Lek et al., 2016) or our internal 
exome database. Variant effect on the nearest splice site was predicted using 
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MaxEntScan (Yeo & Burge, 2004), NNSplice (Reese et al., 1997) and Splice Site 
Finder (based on (Shapiro & Senapathy, 1987)). Structural variants were predicted 
using CANOES (Backenroth et al., 2014) and annotated by AnnotSV (Geoffroy et al., 
2018). We focused on variants consistent with an autosomal recessive inheritance 
(patient compound heterozygous or homozygous). 
The mutations were confirmed by bidirectional Sanger sequencing of purified 
polymerase chain reaction (PCR) products, performed by the GATC Sequencing 
Facilities (Konstanz, Germany). The PCR primers are summarized in Supp. Table S1. 
Enzymatic analyses 
Enzymatic activities of the mitochondrial respiratory chain complexes were measured 
in muscle as reported previously (Bourges et al., 2004). 
The in vitro aminoacylation analyses were done as previously described, by using 
[3H]-labeled lysine (PerkinElmer Life Sciences, 1 mCi/ml) (Francin et al., 2002).  
RNA extraction, cDNA synthesis 
RNA was extracted from primary skin fibroblasts of the patient and a healthy 
unrelated control using RNeasy RNA kit (Qiagen). Then we performed reverse 
transcription of mRNA using the BioRad iScriptTM cDNA Synthesis Kit (BioRad). 
Primers used are summarized in Supp. Table S1. 
Western blot and immunofluorescence of human primary cells 
Primary skin fibroblasts from the patient and control individuals were grown in 
DMEM supplemented with 10% fetal calf serum (FCS) and 1% Penicillin-
streptomycin-glutamin (PSG). Cycloheximide (CHX) pulse chase experiments were 
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done to analyse the stability of the proteins (Kao et al., 2015). Cells were collected at 
different time points (0, 1, 4 and 8 hours) after cycloheximide (Sigma, C7698) 
addition into the cell medium at a final concentration of 100 mg/L. Cells were 
collected in RIPA buffer for western blot and KARS detected with three primary 
antibodies (Kaminska et al., 2007): IgG anti-∆Nter-KARS (polyclonal directed against 
the catalytic domain of the KARS), IgG anti-cytoKARS (polyclonal directed against a 
peptide in the N-terminal part of the cytoplasmic form) and IgG anti-mitoKARS 
(polyclonal directed against a peptide in the N-terminal part of the mitochondrial 
form). Cox4 (Abcam AB14744), Cox2 (Invitrogen 459150) and Grim19 (Santa Cruz 
SC66195) were detected with mouse monoclonal antibodies, NDUFB6 (Abcam 
103531) with a rabbit polyclonal antibody. Quantification of bands in western blot 
was done using ImageLab (BioRad) and the stainfree system after inclusion of 0.5% 
(v/v) 2,2,2-Trichloroethanol (TCE, Sigma T54801) into the polyacrylamide gel and 
revelation by UV of the fluorescent tryptophan residues of the proteins to determine 
total amount of proteins on the membrane (Ladner et al., 2004). 
For immunofluorescence, cells were first incubated with 200 nM Mitotracker red 
(Thermofisher Scientific, M22425), then fixed with 4% formaldehyde and 
permeabilised with 0,5% triton. After blocking with phosphate-buffered saline (PBS) 
20% FCS, the cells were incubated for 1 hr with the primary antibody (Rabbit mAb to 
KARS, Abcam, ab129080), washed 3 times in PBS, incubated for 1 hr with secondary 
antibody (goat anti-rabbit Alexa Fluor 488 IgG, Invitrogen, A-11008) and DAPI, 
washed again in PBS and mounted in Elvanol No-Fade™ mounting medium. 
Observation was done on a Zeiss Axio Observer D1, 400X magnification. 
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KARS and p38 interaction assays by yeast two-hybrid 
The pEG202 (LexA DNA-binding protein fusion, HIS3) or pJG4-5 (GAL1 minimal 
promoter bearing the transcription activation domain, TRP1) yeast two-hybrid vectors 
bearing the p38 or cytoplasmic KARS (protein size 597 aa) cDNA were used in this 
study (Quevillon et al., 1999). The P200L or F263V mutation was introduced into the 
cytoplasmic KARS cDNA by PCR with Phusion High-Fidelity DNA polymerase 
(Thermo Scientific). The plasmids pSF496 (pEG202-KARS-P200L), pSF497 (pJG4-
5-KARS-P200L), pSF498 (pEG202-KARS-F263V) and pSF499 (pJG4-5-KARS-
F263V) sequences were verified (GATC Biotech). The Saccharomyces cerevisiae 
EGY48 (MATα ura3 his3 trp1 LexAop(x6)LEU2) two-hybrid strain bearing the 
pSH18-34 (LacZ reporter plasmid; LexAop(x8)-LacZ, URA3) plasmid was used. 
Yeast cells were transformed by the indicated plasmids and two-hybrid assays were 
done as described (Golemis et al., 2001). The β-galactosidase activity resulting from 
LacZ gene expression was monitored by ONPG (O-nitrophenyl-beta-D-
galactopyranoside) assay (Gietz et al., 1997). 
KARS and p38 interaction assays by coimmunoprecipitation (coIP) 
Cells were grown in DMEM (Gibco Invitrogen, 31885), 10% of FBS and Penicillin 
and Streptomycin (P/S) to full confluence. Cells were rinsed with PBS at 4°C, 
resuspended in non-denaturing lysis buffer (20 mM Tris HCL pH 8; 137 mM NaCl; 
1% Nonidet P-40; 2 mM EDTA) with a protease inhibitor cocktail (Roche 
06538282001) and incubated on ice for 15 min under gentle shaking. The samples 
were then centrifuged at 12,000X g for 20 min at 4°C, protein concentration was 
measured using Qubit® Protein Assay Kit (Life Technologies) and then used for 
immunoprecipitation. 500µg of cell lysate were incubated with KARS antibodies 
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(polyclonal rabbit, (Kaminska et al., 2007)) or with p38 antibodies (polyclonal rabbit, 
(Mirande et al., 1982)) on a rocker shaker overnight at 4°C. The immunocomplexes 
were captured by adding protein G sepharose beads (DUTSCHER 17-0618-05) for 2 h 
at 4°C under gentle shaking. Sepharose G beads were washed 6 times for 5 min with 
the non-denaturing lysis buffer bearing protease inhibitor cocktail, then resuspended 
in 2X Laemmli buffer and boiled for 10 min at 95°C to dissociate the 
immunocomplexes from the beads, prior analysis by western-blot. Actin B (ACTB, 
antibodies from Novus NB600-501SS) was used as a negative control for the coIP and 
as loading control for the Input. 
Results 
Clinical report of a patient 
The female patient, born after an unremarkable pregnancy, was the only child of 
unrelated parents. She had history of motor development delays due to cerebellar 
ataxia. She attended normal schooling. Bilateral congenital deafness was diagnosed 
during the first year at school. Cerebral RMN scan performed at the age of 10 was 
unremarkable. 
The clinical manifestations were stable until the age of 28, when she developed 
additional clinical features with progressive visual impairment. The visual acuity was 
measured at 1.30 LogMAR. Fundus examination showed no retinal involvement, but 
reduced thickness in the temporal region (Figure 1A). Goldman visual fields showed 
concentric decrease of peripheral isopters. The visual acuity worsened significantly 
the years later. Cerebellar syndrome increased progressively and other neurological 
features were observed with a pyramidal syndrome of the 4 limbs, a dystonia, and 
pseudobulbar syndrome. The metabolic screen showed hyperlactatemia. The cerebral 
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RMN scan performed at 28 years old revealed white matter anomalies of the dentate 
nucleus, optic radiations and of the corpus callosum splenium (Figure 1B). 
Electromyography showed a sensitive axonal polyneuropathy of the lower limbs.  
In the hypothesis of a mitochondrial disorder a muscle biopsy was performed which 
showed microscopic features compatible with a mitochondriopathy with no ragged-
red fibers but numerous COX negative fibers (Figure 2A). The study of enzymatic 
complex of the mitochondrial respiratory chain in the skeletal muscle revealed a 
partial deficit in the complexes I (68 %) and IV activities (62 %) (Figure 2B). The 
study of the mitochondrial DNA, including the research of the 3 main mutations, the 
analysis of the deletion and the sequencing of the 22 tRNA, was normal. 
This clinical presentation worsened with a progressive cognitive decline and the 
patient died at the age of 33. 
Whole exome sequencing identified biallelic mutations in the KARS gene of the 
patient. 
In the absence of a molecular diagnosis, we performed whole exome sequencing for 
the patient and her healthy parents. In the proband’s sample, 105.423 genetics variants 
(SNV + Indel) were identified. Bioinformatics analyses narrowed down the number of 
variants to biallelic variants in 5 genes (Supp. Table S2). We focused on two biallelic 
variations (NM_001130089.1: c.683C>T, p.Pro228Leu and c.871T>G, p.Phe291Val) 
in the KARS gene (Figure 3). Sanger sequencing confirmed the mutations and familial 
segregation analysis was consistent with disease transmission (Figure 3A). The 
c.683C>T mutation was previously reported in a patient suspected with a 
mitochondrial disorder (Lieber et al., 2013). The c.871T>G mutation is absent from 
dbSNP, 1000 Genomes, EVS, exAC database and our internal database. This variant 
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was localized in the catalytic domain of the KARS protein (Figure 3) and was 
predicted to be deleterious according to SIFT (Kumar et al., 2009) and PolyPhen-2 
(Adzhubei et al., 2010). The amino acid Phe291 is conserved from metazoan to 
bacteria (E. coli and S. aureus), with the exception of the plant Arabidopsis thaliana, 
and the Pro228 is conserved across metazoan species but not in plant, fungi or in 
bacteria (Figure 3D). 
The mRNA coding for the cytoplasmic and mitochondrial isoforms of KARS are 
present in the fibroblasts of the patient. 
The difference between the two isoforms of KARS is due to alternative splicing, with 
splicing of exon 1 to exon 3 for the cytoplasmic isoform, whereas the mitochondrial 
isoform includes exon 2 (Figure 3B). To determine whether both isoforms of KARS 
were present, the cDNA obtained after reverse transcription of RNAs extracted from 
skin fibroblast of the patient was analyzed by PCR. Using primers from exon 1 to 
exon 4 and exon 2 to exon 3, we observed the two isoforms in the patient and in a 
healthy control. Moreover, exons 5 to 9 were analyzed by sequencing and the two 
mutations were detected in the cDNA of the patient (Figure 4A). We did not observe a 
splicing effect of the two mutations. 
Quantification of KARS mRNA by q-RT-PCR revealed a significant increase of 
mitochondrial KARS in the patient cells compared to the control, whereas no 
difference was observed in the expression of cytoplasmic KARS (Figure 4B). 
KARS protein level is decreased in the cytoplasm of patient fibroblasts  
The mitochondria and cytoplasmic isoforms of KARS differ by their N-terminal part 
(Figure 3C). We observed differences at the mRNA levels indicating an increase of 
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mitochondrial KARS in the patient cells compared to control cells (Figure 4B), 
therefore KARS protein level was analyzed in the patient cells. Patient and control 
fibroblasts were grown in complete medium and total proteins collected for western 
blotting. KARS was detected with antibodies directed either against the catalytic 
domain, thus recognizing mitochondrial and cytoplasmic isoforms or specifically 
against the N-terminal thus specific for each isoform (Figure 4C, Supp. Figure S1). 
The overall expression of KARS is lower in patient cells and this is due to a decrease 
in the cytoplasmic KARS. The level of mitochondrial KARS is only slightly higher in 
patient cells, which correlates with what was observed at the mRNA level (Figure 4). 
This decrease in the cytoplasmic form of KARS was not detected to that extent at the 
mRNA level, this could be due to a higher degradation or decreased stability of the 
KARS-P200L and/or KARS-F263V proteins bearing the patient mutation compared to 
the wild type protein. This result was confirmed by analyzing the stability of the total 
KARS proteins after cycloheximide treatment to inhibit de novo protein synthesis 
(Figure 4D). Immunofluorescence with cytoplasmic KARS antibodies and 
Mitotracker red staining done on fibroblasts revealed no differences in the 
mitochondria staining between the control and the patient cells (Figure 5). The KARS 
signal was very faint in the patient cells (affected) indicating a lower level of 
cytoplasmic KARS compared to the control (ctrl) cells (Figure 5). 
The KARS-P200L and KARS-F263V mutations impair KARS association to the 
multiple aminoacyl-tRNA synthetase (MSC) complex  
In human cells, the aaRS are organized in a multiple aminoacyl-tRNA synthetase 
(MSC) complex (Havrylenko & Mirande, 2015). p38, a core protein responsible for 
assembly of the MSC complex, directly interacts with KARS (Ofir-Birin et al., 2013; 
Quevillon et al., 1999). To better understand the cellular defects linked to the two 
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disease mutations in KARS, we studied their interaction with p38 by yeast two-hybrid 
assays. EGY48 yeast cells were transformed by pEG202 plasmid expressing p38, 
KARS, KARS-P200L or KARS-F263V cDNA, the different LexA DNA-binding 
protein fusions do not activate transcription and expression of the LexA fusions was 
confirmed by the repression assay (Figure 6A) (Golemis et al., 2001). These results 
show that the P200L or F263V mutation did not impair the production of the KARS 
protein. The lack of DNA-binding activity by the p38, KARS, KARS-P200L or 
KARS-F263V protein in fusion with the GAL1 promoter transcriptional activation 
domain cloned in pJG4-5 plasmid was also confirmed (Figure 6A) (Golemis et al., 
2001). The yeast two-hybrid assay was done to determine the interaction between p38 
and KARS, KARS-P200L or KARS-F263V proteins. As previously described, p38 
and KARS display a strong interaction in both combinations of two-hybrid plasmids 
(Quevillon et al., 1999), measured by the ONPG assay to determine the level of lacZ 
transcription (Figure 6B). The β-galactosidase produced by the lacZ reporter for two-
hybrid interaction cleaves the colorless ONPG substrate in galactose and o-
nitrophenol (ONP) that absorbs at 420 nm. The KARS-P200L and KARS-F263V 
mutants display a statistically significant reduced interaction with p38 compared to 
wild-type KARS (Figure 6B). The Pro200 (Pro228 in the mitochondrial KARS) 
residue is in the anticodon-binding domain of KARS close to the Ser207 (Ser235 
mitoKARS) phosphorylation site essential for p38 interaction (Ofir-Birin et al., 2013) 
(Figure 3E). The Phe263 (Phe291 mitoKARS) is at the KARS-p38 interaction 
interface (Figure 3E). These yeast two-hybrid data were confirmed by 
coimmunoprecipitation (Co-IP) analyses done on protein lysates extracted from 
patient and control fibroblasts (Figure 6C). The levels of KARS and p38 proteins were 
lower in the protein lysate (Input) of the patient cells compared to the control. 
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However after immunoprecipitation (IP) of either KARS or p38, these two proteins 
were highly enriched in the IP fractions (Figure 6C), but the interacting protein was 
observed in the control samples and only barely detectable in the patient Co-IP 
samples (Figure 6C).  
These different results show that KARS-P200L and KARS-F263V mutations might be 
pathogenic due to their reduced p38 binding, impairing the association of the 
cytoplasmic KARS Lysine-tRNA synthetase with the MSC complex and affecting its 
function in cytoplasmic protein synthesis.  
The two patient variants are affected in aminoacylation in vitro and the level of 
lysine-rich COX4 and NDUFB6 mitochondrial protein is decreased in patient 
fibroblasts 
To determine the aminoacylation activity, wild-type KARS and the two patient 
variants KARS-P200L or KARS-F263V were produced as recombinant proteins in E. 
coli and purified (Supp. Figure S3). A time course of aminoacylation was conducted 
and the relative aminoacylation activity was determined (Figure 7A). The KARS-
P200L shows a strong decrease in its relative activity compared to wild type KARS 
with only 0.14, and the KARS-F263V displays a two-fold decrease with 0.49 of 
relative activity (Figure 7A). This indicates that in vitro these two variants are affected 
in their aminoacylation level compared to wild-type KARS. 
A decreased activity of complex I and IV of the respiratory chain was observed in the 
patient skeletal muscle (Figure 2B), there was an overexpression of mitochondrial 
KARS in patient cells (Figure 4), and the cytoplasmic KARS-P200L or KARS-F263V 
patient proteins interacted poorly with the MSC complex and are affected in protein 
synthesis activity (Figures 6 and 7A). Therefore, we wondered whether the altered 
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mitochondria function could be due to lower levels of lysine rich members of complex 
I and IV encoded by the nuclear genome and thus translated in the cytoplasm before 
being imported into the mitochondria. Indeed, the cytoplasmic form of the mutated 
KARS seems to be affected with a decreased protein level and impaired association to 
the MSC complex (Figures 4, 5 and 6). To verify this hypothesis, we determined 
which members of complex I and IV were rich in lysine (Supp. Figure S2A) and 
among these we analyzed the protein level of the nuclearly encoded COX4 (11.8% of 
lysine) and NDUFB6 (10,9% of lysine), as well as the nuclearly encoded GRIM19 
with less lysine (4.2%), and COX2 (1.8% of lysine) encoded by the mitochondrial 
genome (Figure 7B). The western blot of total protein extracts from control and 
patient cells shows that the protein levels of COX4 and NDUFB6 but not GRIM19 
and COX2 were decreased in the patient fibroblast (Figure 7B and Supp. Figure S2B). 
This indicates that the mitochondrial dysfunction observed in the patient skeletal 
muscle may indeed be due to defects in the cytoplasmic KARS, leading to a lower 
synthesis of lysine-rich nuclearly encoded complex I and IV proteins. 
Discussion 
The lysyl tRNA synthetase KARS is one of the 37 aa tRNA synthetase genes and one 
of the three dual localized aaRS. A single gene encodes these dual localized aaRS, 
whereas mitochondrial aaRSs are encoded in the nucleus by a specific gene different 
from those coding for the cytosolic aaRSs (Bonnefond et al., 2005). The two mRNAs 
of KARS are transcribed by an alternative splicing and are translated in the cytoplasm 
to form the cytoplasmic isoform and the precursor of the mitochondrial isoform 
bearing the MTS (mitochondria targeting sequence) (Figure 3). The mature form of 
mitochondrial KARS is produced during mitochondrial import by cleavage of the N-
terminal MTS of the precursor (Dias et al., 2012). The cytoplasmic isoform represents 
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approximately 70% and the mitochondrial isoform about 30 % of the mature transcript 
from the KARS gene (Tolkunova, Park, Xia, King, & Davidson, 2000).  
A mitochondrial defect phenotype associated with KARS mutations 
Mitochondrial disorders comprise a heterogeneous group of diseases due to 
mitochondrial dysfunctions that can have pleiotropic effects. The features can include 
leukoencephalopathy, sensorineural deafness, optic atrophy, and ataxia. Less than 15-
30 % of suspected mitochondrial disorders are due to a mitochondrial DNA anomaly 
(Dimauro & Davidzon, 2005; Kirby & Thorburn, 2008). More than 1000 nuclear 
genes encode proteins necessary for mitochondrial function that can explain the 
remaining cases (Human MitoCarta2.0). Among the 37 human aaRSs, mutations in 
mitochondrial and dual localized aaRS are associated with different organ 
involvements and could be responsible for a defect in mitochondrial protein synthesis 
(Diodato et al., 2014; Nafisinia et al., 2017; Sauter et al., 2015).  
As no mitochondrial DNA mutations or deletion were detected in the patient 
presenting clinical manifestations compatible with a mitochondrial defect, we 
performed whole exome sequencing and identified biallelic mutations in the KARS 
gene, with one novel mutation. 
Sixteen biallelic KARS mutations are linked to a large spectrum of neurologic or 
neurosensorial diseases (Table 1). Mutations in this gene were initially described to be 
associated with a peripheral neuropathy (McLaughlin et al., 2010) and non syndromic 
hearing impairment (Santos-Cortez et al., 2013). More complex phenotypes were also 
reported, including clinical associations evocative of a mitochondrial disorder (Kohda 
et al., 2016; Lieber et al., 2013; McMillan et al., 2015; Murray et al., 2017; Verrigni et 
al., 2017; Zhou et al., 2017). Our patient presented with an overlapping phenotype 
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with those previously described with hearing loss, abnormal white matter, lactic 
acidosis, and combined enzymatic defects of respiratory chain complexes. 
Nevertheless she had an atypical presentation with a stable evolution until 28 years 
old and worsening clinical manifestations in few years. In addition, she had visual 
impairment with white matter anomalies of optic radiations and optic neuropathy not 
previously reported. 
Impact of the identified KARS mutations  
In higher eukaryotes at least nine aaRSs, including the cytoplasmic KARS isoform 
belong to the MSC complex with three accessory proteins (p18, p38 and p43) 
(Havrylenko & Mirande, 2015). 
Among the two identified variants in KARS gene, the p.Pro228Leu mutation was 
previously described (Lieber et al., 2013) and a recent functional analysis was 
performed, showing defect in mitochondria translation (Ruzzenente et al., 2018). Here 
we show that this KARS-Pro228Leu is severely affected for aminoacylation in vitro. 
The Pro228 amino acid is localized in the anticodon-binding domain of KARS close 
to the P-S207 phosphorylation site essential for p38 interaction and association with 
the MSC (Ofir-Birin et al., 2013). The P-S207 form of KARS is released from the 
MCS and translocates to the nucleus where it is associated to transcriptional activities. 
Among the cellular functions of this P-S207 KARS, its role in the production of the 
second messenger Ap4A has already been studied in the eye in various conditions 
such as a biomarker for raised intra ocular pressure in glaucoma were higher levels of 
Ap4A were observed as well as in the tears from patients suffering of other ocular 
pathologies, as dry eye and congenital aniridia (Castany et al., 2011; Guzman-
Aranguez et al., 2007; Peral et al., 2006; Peral et al., 2015). The potential therapeutic 
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effects of dinucleotide polyphosphates have been proposed for various eye conditions 
including regulation of intra ocular pressure in a mouse model (Carracedo et al., 2016; 
Crooke et al., 2017). In this respect, it is interesting to underline that our patient 
presented with a non glaucomatous optic neuropathy developed in the context of a 
down regulation of KARS effectors suggesting that Ap4A supplementation could 
have been protective if Ap4A deficiency had been proven. This points to the probably 
subtle equilibrium of the Ap4A intraocular levels in various eye conditions (ie: 
glaucomatous versus non glaucomatous ganglion cell loss) as well as to the complex 
pathogenesis underlying these conditions. The known link of P-207 KARS regulating 
MITF, a gene mutated in Waardenburg syndrome type 2 and Tietze syndrome for 
which neurosensory hearing loss is well described, is also highly interesting as our 
patient first clinical manifestation was deafness pointing here to a link of this 
condition with this pathway. The p.Phe291Val mutation is a novel variant that hits the 
catalytic domain of the enzyme and affects an amino acid residue highly conserved 
among diverse metazoan species (Figure 3D) (http://misynpat.org) (Moulinier et al., 
2017). The Phe291 amino acid is at the KARS-p38 interaction interface (Figure 3E). 
The KARS-Phe291Val variant has a 2-fold decrease in relative aminoacylation 
activity compared to wild type KARS. 
The study of the expression level of both KARS isoforms (cytoplasmic and 
mitochondrial) was not performed for the other human KARS mutations previously 
reported. To better understand the disease mechanism of the mutations identified in 
our patient, we studied the impact of both mutations in the two KARS isoforms. 
Investigations on skin fibroblasts of the patient showed that both KARS isoforms are 
present at the mRNA level and that the mutations do not affect the splicing. 
Interestingly, we observed a similar level of cytoplasmic KARS mRNA in the patient 
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and control cells, whereas the cytoplasmic KARS protein level was decreased due to 
higher degradation or decreased stability of the mutant proteins, which could be due to 
lack of association to the MSC complex. Indeed, by using the yeast-two hybrid assay, 
we demonstrated that both mutations are associated with a significantly reduced 
interaction between cytoplasmic KARS and the core protein p38 of the MSC complex. 
These data were confirmed by coimmunoprecipitation assays on lysates from patient 
fibroblasts, showing that less KARS proteins were interacting with p38 compared to 
the control. In parallel to these effects on the cytoplasmic isoform of KARS, we 
observed an increase in mitochondrial KARS at the mRNA level and to some extent at 
the protein level. These results suggest that more mitochondrial KARS could be 
imported into the mitochondria and transformed into its active form. However, this 
cannot compensate for the lysine incorporation during the cytoplasmic production of 
respiratory chain proteins encoded by the nuclear genome, leading to the reduced level 
of cytochrome C oxidase COX4 subunit and to the partial decrease of complex I and 
IV activity in the skeletal muscle of the patient. A similar combined complex 
deficiency and reduction of cytochrome C oxidase was already reported for other 
patients with KARS mutations (Kohda et al., 2016; Verrigni et al., 2017).  
In conclusion, we report biallelic mutations in the KARS gene, one of which had not 
been previously reported, in a patient presenting cerebellar ataxia and optic 
neuropathy in addition to the sensory deafness and neurological features already 
described. Our results show the implication of both mutations in the phenotype of the 
patient. However, further studies are needed to investigate more in details which 
proteins of the respiratory chain are affected and to what extent.  
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Data generated or analyzed during this study are included in the published article and 
the corresponding supplementary data. The raw sequencing data generated in the 
course of this study are not publicly available due to the protocol and the 
corresponding consents used that did not include such information. KARS’ variants 
have been submitted to ClinVar with the following accession numbers 
SCV000808060 and SCV000808061 (https://www.ncbi.nlm.nih.gov/clinvar/). 
Anonymized NGS data and genomic variant data files will be made available upon 
request from qualified investigators studying the molecular basis of genomic 
disorders. Datasets can be obtained via the corresponding author on reasonable 
request. 
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Figures 
Figure 1: Fundus photograph and Brain MRI of the patient A) Fundus photographs 
of the patient showing optic neuropathy with symmetric temporal wedges of disc pallor. B) 
Brain MRI: axial FLAIR weighted images (a-c), axial diffusion weighted images (d-f) and 
Apparent Diffusion Coefficient maps (g-i) : Hyperintense FLAIR (a-c) lesions of both 
dentate nucleus (arrow), optic radiations (arrow head) and of the corpus callosum splenium 
(cross). The lesions are heterogeneous on diffusion weighted images (d-f), with mild 
hyperintense areas (circle) (d-f) corresponding to elevated diffusion coefficient on Apparent 
Diffusion Coefficient maps (circle) (g-i) and more hyperintense areas (star) (d-f) 
corresponding to restricted diffusion coefficient on Apparent Diffusion Coefficient maps 
(star) (g-i). 
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Figure 2: Morphologic and enzymatic analyses on muscle biopsy of the patient A) 
No ragged-red fibers were observed on modified Gomori trichrome staining (a), but 
numerous COX negative fibers were present (star). Scale bar 50 µm. B) Activity of the 
respiratory chain complexes (normalized to citrate synthase activity), showing partial deficit 
of complex I (68% of the reference range mean) and complex IV (62%). Abnormal activity 
ratios confirm imbalance of complexes. 
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Figure 4: Expression of KARS at mRNA and protein level, from skin fibroblasts of 
the patient A) cDNA sequence after amplification from exon 5 to 9 (using primers 5F and 
9R) showing the two mutations. B) Quantification of KARS mRNA showed an increased 
amount of mitochondrial KARS mRNA in the patient compared to controls. C) Expression 
of mitochondrial and cytoplasmic forms of KARS proteins in control (ctrl) and patient 
(affected) fibroblasts observed by western blot. KARS was detected with three different 
antibodies recognizing either both isoforms of KARS when directed against the catalytic 
domain (total) or specifically the cytoplasmic or mitochondrial isoforms. The asterisk 
indicates the band at the right size. The stainfree loading control shows the total amount of 
proteins loaded on the gel and was used for quantification. Quantification of total, 
cytoplasmic (cyto) and mitochondrial (mito) isoforms of KARS in patient cells as detected 
with the three antibodies mentioned above and represented as percentage (%) of the amount 
of KARS in control cells (ctrl). Values are the mean of five experiments. Statistical analyses 
were done with the T-Test and the p-values were determined, *: p< 0,05, ** p<0,01. D) 
Control (ctrl) and patient (affected) cells were incubated with cycloheximide (100 mg/L) for 
0 to 8 hours before being collected and anti- KARS western blot was performed on the cell 
lysates. The total protein level of KARS was determined relative to the house keeping 
protein GAPDH used as loading control. 
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Figure 5: Immunofluorescence on patient’s skin fibroblasts A decreased amount of 
cytoplasmic KARS was observed in patient (affected) fibroblasts compared to control (ctrl) 
by anti-KARS immunofluorescence microscopy. Cells were grown on coverslips, stained 
with mitotracker red and observed under a fluorescence microscope after anti-KARS 
antibodies labeling. The immunofluorescence staining shows mostly the cytoplasmic KARS 
proteins in control fibroblasts and a decreased fluorescence staining was observed in the 
patient cells. Images were taken with a 400X magnification, scale bar 5 µm. 
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Figure 6: The mutant KARS proteins show decreased interaction with p38 A) The 
EGY48 yeast cells bearing the pSH18-34 LacZ reporter plasmid were transformed by 
pEG202 plasmid expressing p38, KARS, KARS-P200L or KARS-F263V cDNA in fusion 
with the LexA DNA-binding protein, and there was no production of β-galactosidase, 
showing that there is no self-activation. The EGY48 yeast cells bearing the pJK101 control 
plasmid were transformed by pEG202 plasmid expressing p38, KARS, KARS-P200L or 
KARS-F263V cDNA, and expression of the LexA fusions was confirmed by this repression 
assay. The EGY48 yeast cells bearing the pSH18-34 LacZ reporter and pEG202-LexA 
plasmids were transformed by pJG4-5 plasmid expressing p38, KARS, KARS-P200L or 
KARS-F263V cDNA in fusion with the GAL1 promoter transcriptional activation domain; 
no β-galactosidase activity was observed showing that there is no self-DNA binding. B) The 
two-hybrid interaction assay was done in EGY48 yeast cells bearing the pSH18-34 LacZ 
reporter transformed by pEG202-p38 or pJG4-5-p38 and by pJG4-5- or pEG202-KARS, -
KARS-P200L or -KARS-F263V plasmid respectively, and the β-galactosidase activity was 
determined by the ONPG colorimetric assay measuring the optical density (OD) at 420 nm 
that corresponds to ONP production. The KARS missense mutations impair interaction with 
p38. Statistical analyses were done with the T-Test and the p-values were determined, ***: 
p<0,005. C) Coimmunoprecipitation (Co-IP) between p38 and KARS, done in primary 
human fibroblasts. Control (ctrl) or patient (affected) fibroblasts were collected and lysed in 
non-denaturing lysis buffer. Immunoprecipitation was performed on the total whole lysates 
using antibodies directed against KARS (Co-IP KARS) or p38 (Co-IP p38), or without 
antibodies (Neg-IP) as a control. Proteins were detected by western blot in the whole cell 
lysates (Input) and the immunoprecipitations (neg-IP, Co-IP KARS and Co-IP p38) using 
the KARS and p38 antibodies. Actin B (ACTB) was used as a negative control. 
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Figure 7: KARS variants display decreased aminoacylation efficiency and impact 
synthesis of lysine-rich nuclear encoded mitochondrial proteins. A) Time course of 
aminoacylation by KARS wild type and the two variants. Aminoacylations were performed 
with 10 nM of enzyme (KARS, KARS-P200L or KARS-F263V, as indicated), 4 µM of total 
yeast tRNA and 0.5 µM of [3H]-Lysine, the values are the mean of three experiments with 
standard deviation error bars. The relative catalytic activity of the variants compared to the 
wild type KARS is indicated. B) Expression of proteins from the mitochondrial chain in 
control (ctrl) and patient (affected) fibroblasts. Cells were harvested and western blot against 
GRIM19, COX4, NDUFB6 and COX2 performed. Content in lysine (K) as % of total 
number of amino acids indicated as well as whether the gene is in the nuclear or 
mitochondrial genome. 
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Tables 
Table 1: Reported mutations in the KARS gene associated with the phenotypes (hmz: 
homozygous; htz: heterozygous; cmpdt htz: compound heterozygous). 
McLaughlin et 
al., 2010 
Santos-
Cortes et 
al., 2013 
Lieber et al., 
2013 
McMillan 
et al., 2014 
Retterer 
et al., 
2016 
Khoda et 
al., 2016 
Verrigni 
et al., 
2016 
Chen et 
al., 2016 
Jung et 
al., 2017 
Zhou et al., 
2017 
Murray et 
al., 2017 
Number of 
patients 
2 from 2 
families 
3 from 3 
families 
1 1 2 1 1 3 1 
2 from one 
family  
2 from one 
family 
Microcephaly + + 
Developmental 
delay + (1) + + + + + 
Peripheral 
neuropathy + (2) 
Other 
neurological 
features 
+ (hypotonia, 
dystonia) 
+ 
(seizures) 
+ 
+ 
(myopathy
) 
+ (cognitive 
decline) 
+ (hypotonia, 
seizures, 
ataxia) 
Mitochondrial 
defect 
Increased 
mtDNA in 
muscle 
Combined 
complex 
deficiencies 
Combined 
complex 
deficiencie
s 
Cerebral 
anomalies 
+ 
(symmetric 
abnormal 
subcortical 
white 
matter, 
hypogenesi
s of corpus 
callosum) 
normal 
+ (symmetric 
signal 
anomalies in 
the frontal 
white matter 
periventricula
r and the 
corpus 
callosum) 
CT 
(calcifications 
of the left 
occipitopariet
al junction) 
Hearing 
impairment + + + + + + 
Ophthalmologic 
features  
+ (strabismus, 
ophtalmoplegia
) 
+ (severe 
visual loss, 
pendular 
nystagmus) 
normal 
Cardiomyopath
y + 
Other features 
Vestibular 
Schwannoma, 
dysmorphic 
features (1) 
Mitochondri
al cytopathy 
 
Mutation in 
KARS gene 
NM_001130089.
1 
cmpdt htz : 
c.398T>A 
(p.L133H) 
c.524_525dupT
T 
htz: 
c.906C>G 
(p.I302M) 
hmz : 
c.517T>C 
(p.Y173H) 
hmz : 
c.1129G>
A 
(p.D377N)  
cmpdt htz : 
c.683C>T 
(p.P228L) 
c.1760C>T 
(p.T587M) 
cmpdt htz : 
c.1396C>T 
(p.R466W) 
c.1657G>
A 
(p.E553K) 
htz: 
c.972G>
A 
(p.M324I
) htz: 
del ex 5-8  
cmpdt htz : 
c.1037T>C 
(p.I346T) 
c.1427T>A 
(p.V476D) 
cmpdt htz : 
c.1133T>
A 
(p.L378H) 
c.1253C>
G 
(p.P418R) 
htz : 
c.1409G>
T 
(p.R470M
)  
htz : 
c.1450T>
G 
(p.C484G)  
cmpdt htz : 
c.1430G>A 
(p.R477H) 
c.1513C>T 
(p.P505S) 
c.1466T>G 
(p.F489C) 
c.1577C>T 
(p.A526V) 
